Giulia Zanetti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Giulia Zanetti has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Anne Paulien Drenth
Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
15 shared publications - Bjørn Siteur
Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands
15 shared publications - Catrin Lutz
Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
15 shared publications - Chi-Chuan Lin
School of Molecular and Cellular Biology, Centre for Plant Sciences and Astbury Centre for Structural Molecular Biology University of Leeds Leeds LS2 9JT UK
15 shared publications - Daniel Zingg
Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
15 shared publications - Eline van der Burg
Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
15 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Beyond Static Screens: Optical Pooled Screening of Signaling Dynamics Using Time-lapse FLIM
Genetic screens are powerful tools for linking gene perturbations to cellular phenotypes, yet most pooled imaging approaches rely on static endpoint measurements. Here, we extend optical pooled screening to dynamic signaling phenotypes by combining time-lapse Förster resonance energy transfer–fluorescence lifetime imaging microscopy (FRET-FLIM) with optical enrichment and downstream genotyping.To enable high-throughput live-cell screening of dynamic phenotypes, we optimized and benchmarked all major steps in the pipeline. We developed FAST-HIPPOS, a Fiji-based automated analysis pipeline that rapidly segments hundreds of thousands of cells, extracts single-cell lifetime time traces, and identifies phenotypic hits in minutes for targeted photoactivation. We further established a robust phototagging strategy using the photoactivatable dye PA-JaneliaFluor646, providing bright, cloning-free labeling across diverse cell types. Benchmarking further demonstrated high sorting fidelity with low false-positive rates and efficient recovery of guide RNAs from as few as 200 sorted cells with minimal PCR bias.Applying this platform to cAMP signaling in HeLa cells using a custom CRISPR library recovered the expected primary regulators of β-adrenergic signaling—ADRB2, GNAS, and ADCY6—with no gene-level false positives. Together, these optimizations establish a robust general framework for screening dynamic phenotypes that is easily adaptable to other live-cell readouts beyond FRET-FLIM and cAMP.
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessBeyond Static Screens: Optical Pooled Screening of Signaling Dynamics Using Time-lapse FLIM
Genetic screens are powerful tools for linking gene perturbations to cellular phenotypes, yet most pooled imaging approaches rely on static endpoint measurements. Here, we extend optical pooled screening to dynamic signaling phenotypes by combining time-lapse Förster resonance energy transfer–fluorescence lifetime imaging microscopy (FRET-FLIM) with optical enrichment and downstream genotyping.To enable high-throughput live-cell screening of dynamic phenotypes, we optimized and benchmarked all major steps in the pipeline. We developed FAST-HIPPOS, a Fiji-based automated analysis pipeline that rapidly segments hundreds of thousands of cells, extracts single-cell lifetime time traces, and identifies phenotypic hits in minutes for targeted photoactivation. We further established a robust phototagging strategy using the photoactivatable dye PA-JaneliaFluor646, providing bright, cloning-free labeling across diverse cell types. Benchmarking further demonstrated high sorting fidelity with low false-positive rates and efficient recovery of guide RNAs from as few as 200 sorted cells with minimal PCR bias.Applying this platform to cAMP signaling in HeLa cells using a custom CRISPR library recovered the expected primary regulators of β-adrenergic signaling—ADRB2, GNAS, and ADCY6—with no gene-level false positives. Together, these optimizations establish a robust general framework for screening dynamic phenotypes that is easily adaptable to other live-cell readouts beyond FRET-FLIM and cAMP.
- Open Access
- 1 May 2026
- Published by Wiley in FEBS Open Bio
Optimizing photoactivation of PA ‐ mCherry for optical pooled CRISPR screens
Optical pooled CRISPR screens have become an attractive tool for the rapid identification of genes involved in biological processes. In such screens, mixed populations of cells, each with a single gene knocked out, are screened by microscopy for phenotypes of interest. Identified hit cells can then be tagged by photoactivation of a co‐expressed marker, such as PA‐mCherry, and subsequently isolated by FACS to identify the responsible guide RNA by next‐generation sequencing. Photoactivation is typically performed by selective irradiation of cells with UV light, using either a digital mirror device (DMD), an external fixed UV laser, or, conveniently, by using the 405 nm laser line present in most confocal scanning microscopes. In this study, the latter approach is optimized for PA‐mCherry, a bright red phototag used by us and others in optical pooled screens. We find that although normal scanning with intense 405 nm light can rapidly activate PA‐mCherry, it also leads to rapid photobleaching. Instead, much higher cellular brightness is achieved by limiting intensity and pixel dwell time during scanning, as well as by slightly defocusing the laser. These results should help optimize cell tagging for genotype–phenotype mapping in optical pooled screens, as well as for other applications.
- 1 May 2026
- Published by Wiley in FEBS Open Bio
Open AccessOptimizing photoactivation of PA ‐ mCherry for optical pooled CRISPR screens
Optical pooled CRISPR screens have become an attractive tool for the rapid identification of genes involved in biological processes. In such screens, mixed populations of cells, each with a single gene knocked out, are screened by microscopy for phenotypes of interest. Identified hit cells can then be tagged by photoactivation of a co‐expressed marker, such as PA‐mCherry, and subsequently isolated by FACS to identify the responsible guide RNA by next‐generation sequencing. Photoactivation is typically performed by selective irradiation of cells with UV light, using either a digital mirror device (DMD), an external fixed UV laser, or, conveniently, by using the 405 nm laser line present in most confocal scanning microscopes. In this study, the latter approach is optimized for PA‐mCherry, a bright red phototag used by us and others in optical pooled screens. We find that although normal scanning with intense 405 nm light can rapidly activate PA‐mCherry, it also leads to rapid photobleaching. Instead, much higher cellular brightness is achieved by limiting intensity and pixel dwell time during scanning, as well as by slightly defocusing the laser. These results should help optimize cell tagging for genotype–phenotype mapping in optical pooled screens, as well as for other applications.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Key resources. List of antibodies, commercial assays, experimental models, reagents, and software used in this study.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Key resources. List of antibodies, commercial assays, experimental models, reagents, and software used in this study.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Supplementary Methods related to FLAG and HALO tag constructs.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Supplementary Methods related to FLAG and HALO tag constructs.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Data supporting the functional analysis of C-terminal F703–S704 combination Fgfr2 variants using in vitro and in vivo methods.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Data supporting the functional analysis of C-terminal F703–S704 combination Fgfr2 variants using in vitro and in vivo methods.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Proteins identified in Fgfr2-GFP immunoprecipitation samples using MS-based proteomics. The table shows all proteins identified using global proteomics on GFP-immunoprecipitation samples using NMuMG cells expressing GFP, Fgfr2FL-GFP, or Fgfr2DE18- GFP.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Proteins identified in Fgfr2-GFP immunoprecipitation samples using MS-based proteomics. The table shows all proteins identified using global proteomics on GFP-immunoprecipitation samples using NMuMG cells expressing GFP, Fgfr2FL-GFP, or Fgfr2DE18- GFP.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Histological examination of mammary glands injected with C-terminal F703–S704 Fgfr2 motif variants.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Histological examination of mammary glands injected with C-terminal F703–S704 Fgfr2 motif variants.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
FACS data incl. gating strategy supporting the HALO Fgfr2 internalization analysis and data supporting the biochemical Fgfr2-CT assays
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
FACS data incl. gating strategy supporting the HALO Fgfr2 internalization analysis and data supporting the biochemical Fgfr2-CT assays
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Data supporting the mapping of the F703–S704 motif in the Fgfr2 C-tail using FACS (gating strategy shown) and RNA-seq.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Data supporting the mapping of the F703–S704 motif in the Fgfr2 C-tail using FACS (gating strategy shown) and RNA-seq.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Exact P values corresponding to Fig. 4B.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Exact P values corresponding to Fig. 4B.